Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Aptevo Therapeutics (Nasdaq: APVO), a clinical-stage biotechnology company, has completed its previously announced registered direct offering, raising $2.0 million through the sale of 2,324,000 shares of common stock at $0.862 per share.
The offering was conducted at-the-market under Nasdaq rules, with Roth Capital Partners serving as the exclusive placement agent. The company plans to utilize the net proceeds for continued clinical development of its product candidates, working capital, and general corporate purposes.
The offering was made through a shelf registration statement on Form S-3 (File No. 333-284969) previously filed with the SEC. Aptevo specializes in developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies.
Aptevo Therapeutics (Nasdaq: APVO), una società biotecnologica in fase clinica, ha completato la sua offerta diretta registrata precedentemente annunciata, raccogliendo 2,0 milioni di dollari tramite la vendita di 2.324.000 azioni ordinarie al prezzo di 0,862 dollari per azione.
L'offerta è stata effettuata sul mercato secondo le regole del Nasdaq, con Roth Capital Partners come agente di collocamento esclusivo. La società intende utilizzare i proventi netti per il proseguimento dello sviluppo clinico dei suoi candidati farmaci, per il capitale circolante e per scopi aziendali generali.
L'offerta è stata effettuata tramite una dichiarazione di registrazione a scaffale sul modulo S-3 (File No. 333-284969) precedentemente depositata presso la SEC. Aptevo è specializzata nello sviluppo di nuove terapie immuno-oncologiche basate sulle sue tecnologie proprietarie ADAPTIR® e ADAPTIR-FLEX®.
Aptevo Therapeutics (Nasdaq: APVO), una compañía biotecnológica en etapa clínica, ha completado su oferta directa registrada previamente anunciada, recaudando 2,0 millones de dólares mediante la venta de 2.324.000 acciones comunes a 0,862 dólares por acción.
La oferta se realizó en el mercado conforme a las normas del Nasdaq, con Roth Capital Partners como agente de colocación exclusivo. La compañía planea utilizar los ingresos netos para continuar el desarrollo clínico de sus candidatos a productos, capital de trabajo y fines corporativos generales.
La oferta se hizo a través de una declaración de registro en estantería en el Formulario S-3 (Archivo No. 333-284969) presentada previamente ante la SEC. Aptevo se especializa en el desarrollo de terapias inmunooncológicas novedosas basadas en sus tecnologías propietarias ADAPTIR® y ADAPTIR-FLEX®.
Aptevo Therapeutics (나스닥: APVO)는 임상 단계의 생명공학 회사로서, 이전에 발표한 등록 직접 공모를 완료하여 2백만 달러를 조달했으며, 보통주 2,324,000주를 주당 0.862달러에 판매했습니다.
이번 공모는 나스닥 규정에 따라 시장가로 진행되었으며, Roth Capital Partners가 단독 배정 대행사로 참여했습니다. 회사는 순수익을 제품 후보물질의 임상 개발 지속, 운전자본 및 일반 기업 목적에 사용할 계획입니다.
공모는 SEC에 사전 제출된 서류번호 333-284969의 S-3 양식 등록 명세서를 통해 이루어졌습니다. Aptevo는 독자적인 ADAPTIR® 및 ADAPTIR-FLEX® 플랫폼 기술을 기반으로 한 혁신적인 면역종양 치료제 개발에 전문화되어 있습니다.
Aptevo Therapeutics (Nasdaq : APVO), une société biotechnologique en phase clinique, a finalisé son offre directe enregistrée précédemment annoncée, levant 2,0 millions de dollars grâce à la vente de 2 324 000 actions ordinaires au prix de 0,862 dollar par action.
L'offre a été réalisée sur le marché conformément aux règles du Nasdaq, avec Roth Capital Partners en tant qu'agent de placement exclusif. La société prévoit d'utiliser le produit net pour poursuivre le développement clinique de ses candidats-médicaments, le fonds de roulement et des fins corporatives générales.
L'offre a été faite via une déclaration d'enregistrement sur étagère sur le formulaire S-3 (dossier n° 333-284969) déposée précédemment auprès de la SEC. Aptevo se spécialise dans le développement de nouvelles thérapies immuno-oncologiques basées sur ses technologies propriétaires ADAPTIR® et ADAPTIR-FLEX®.
Aptevo Therapeutics (Nasdaq: APVO), ein biotechnologisches Unternehmen in der klinischen Phase, hat sein zuvor angekündigtes registriertes Direktangebot abgeschlossen und dabei 2,0 Millionen US-Dollar durch den Verkauf von 2.324.000 Stammaktien zu je 0,862 US-Dollar pro Aktie eingenommen.
Das Angebot wurde gemäß den Nasdaq-Regeln am Markt durchgeführt, wobei Roth Capital Partners als exklusiver Platzierungsagent fungierte. Das Unternehmen plant, die Nettoerlöse für die weitere klinische Entwicklung seiner Produktkandidaten, das Betriebskapital und allgemeine Unternehmenszwecke zu verwenden.
Das Angebot erfolgte über eine zuvor bei der SEC eingereichte Shelf-Registrierungserklärung auf Formular S-3 (Aktenzeichen 333-284969). Aptevo ist auf die Entwicklung neuartiger Immunonkologie-Therapeutika spezialisiert, die auf den firmeneigenen Plattformtechnologien ADAPTIR® und ADAPTIR-FLEX® basieren.
- Secured $2.0 million in additional funding
- Successfully completed registered direct offering
- Funds allocated for clinical development advancement
- Low offering price of $0.862 per share indicates weak market position
- Small offering size of $2.0M suggests investor interest
- Potential dilution for existing shareholders
Insights
Aptevo secured $2M funding at premium pricing, representing ~60% of market cap with significant dilution impact for clinical development.
Aptevo Therapeutics has closed a $2.0 million registered direct offering, issuing 2,324,000 shares at $0.862 per share. This financing represents a significant development for the company, which has a current market capitalization of approximately
The offering price of
For context, this
According to the announcement, the company intends to allocate these funds toward three specific areas:
- Continued clinical development of product candidates
- Working capital requirements
- General corporate purposes
For a clinical-stage biotechnology company focused on immune-oncology therapeutics with proprietary ADAPTIR and ADAPTIR-FLEX platforms, securing capital is essential for advancing pipeline candidates through development stages.
Roth Capital Partners served as the exclusive placement agent for this transaction, which was conducted as a registered direct offering under Nasdaq rules, utilizing an existing shelf registration statement that was previously filed with the SEC.
SEATTLE, WA / ACCESS Newswire / April 22, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, announced the closing of its previously announced offering of 2,324,000 shares of the Company's common stock in a registered direct offering (the "offering") at a purchase price of
Roth Capital Partners acted as the exclusive placement agent for the offering.
Gross proceeds from the offering were approximately
A shelf registration statement on Form S-3 (File No. 333-284969) relating to the shares of common stock to be issued in the registered direct offering was previously filed with the Securities and Exchange Commission (the "SEC") and is currently effective. The registered direct offering was made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement, relating to the registered direct offering that was filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, on the SEC's website at http://www.sec.gov or by contacting Roth Capital Partners, LLC at 888 San Clemente Drive, Newport Beach CA 92660, by phone at (800) 678-9147 or by email at rothecm@roth.com.
This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the shares of common stock, nor will there be any sale of the shares of common stock in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.
About Aptevo Therapeutics
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The company has two clinical candidates. Mipletamig is currently being evaluated in RAINIER, a Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation ("orphan status") for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates were created from two proprietary platforms, ADAPTIR® and ADAPTIR-FLEX® The Aptevo mission is to improve treatment outcomes and transform the lives of cancer patients. For more information, please visit www.aptevotherapeutics.com.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, statements regarding the use of proceeds of the offering, and any other statements containing the words "may," "continue to," "believes," "expects," "optimism," "potential," "designed," "promising," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Aptevo's current intentions, beliefs, and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo's expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement.
There are several important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; uncertainties related to market conditions, the satisfaction of customary closing conditions related to the offering, compliance with Nasdaq listing requirements, and changes in regulatory, social, macroeconomic, and political conditions. For instance, actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the results of preliminary data and preclinical studies being predictive of the results of later-stage clinical trials, initiation, enrollment and maintenance of patients, and the completion of clinical trials, the availability and timing of data from ongoing clinical trials, the trial design includes combination therapies that may make it difficult to accurately ascertain the benefits of mipletamig, expectations for the timing and steps required in the regulatory review process, expectations for regulatory approvals, the impact of competitive products, our ability to enter into agreements with strategic partners or raise funds on acceptable terms or at all and other matters that could affect the availability or commercial potential of Aptevo's product candidates, business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises such as the coronavirus (referred to as COVID-19), geopolitical risks, including the current war between Russia and Ukraine, war between Israel and Hamas, and macroeconomic conditions such as economic uncertainty, rising inflation and interest rates, increased market volatility and decreased consumer confidence. These risks are not exhaustive, Aptevo faces known and unknown risks. Additional risks and factors that may affect results are set forth in Aptevo's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and its subsequent current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Aptevo's expectations in any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not assume any obligation to update any forward-looking statement to reflect new information, events, or circumstances.
CONTACT:
Miriam Weber Miller
Aptevo Therapeutics
Email: IR@apvo.com or Millerm@apvo.com
Phone: 206-859-6628
SOURCE: Aptevo Therapeutics
View the original press release on ACCESS Newswire
FAQ
How much did Aptevo Therapeutics (APVO) raise in its April 2025 registered direct offering?
What is the price per share for APVO's April 2025 registered direct offering?
How will Aptevo Therapeutics use the proceeds from its 2025 registered direct offering?
Who acted as the placement agent for Aptevo's April 2025 offering?
